A Study of SNP-ACTH (1-39) Gel in Patients With Primary Membranous Nephropathy

NCT05696613

Status	RECRUITING
Phase	Phase 3
Sponsor	Cerium Pharmaceuticals, Inc.
Enrollment	148 participants

Key Eligibility Criteria

Inclusion (7)

- Biopsy-proven membranous glomerulonephritis or a diagnosis of MN in patients with Nephrotic Syndrome and a positive anti PLA2R antibody test.
- Patients classified to be at a High Risk for progressive loss of kidney function, as defined by Kidney Disease Improving Global Outcomes (KDIGO) 2021-Glomerular Diseases Guideline.
- eGFR by Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula e40 mL/min/1.73 m\^2
- Patients who have had CR or PR in response to immunosuppressive therapy, but then relapsed can participate in the study if it has been more than 3 months since their last dose of high dose glucocorticoids, calcineurin inhibitors or mycophenolate mofetil
- Patients who have had CR or PR in response to IS therapy, but then relapsed can participate in the study if it has been more than 6 months since their last dose of chlorambucil or cyclophosphamide

... and 2 more (see full listing online)

Exclusion (6)

- Secondary membranous nephropathy as defined by history, physical exam, kidney biopsy results or serologies.
- Patients who have had a e 50% reduction in serum titers of PLA2R auto-antibody within 1 year before screening.
- Type 1 or 2 diabetes mellitus
- Patients who must be initiated on drugs likely to affect renal function if not properly dosed.
- Surgery within 1 month of study entry

... and 1 more (see full listing online)

Locations (31 total)

Academic Medical Research Institute, Los Angeles, California, United States
North America Research Institute, San Dimas, California, United States
Valiance Clinical Research, Tarzana, California, United States
... and 28 more locations